Investigational drug · Phase 3
DP303c
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
9
Any phase or sponsor naming "DP303c"
First trial start
2023
Jul 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DP303c", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Breast Cancer
- Advanced Solid Tumors
- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
- Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
- HER2-positive Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DP303c" as an intervention, largest first.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07241936 · 444 participants (planned) · Start Nov 13, 2025 · Primary completion Oct 30, 2027
Drug: sirolimus (albumin-bound); DP303c and 3 more · For: Advanced Solid Tumors
Sites: Shanghai, China
- DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerPivotal-lookingRecruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06313086 · 442 participants (planned) · Start Mar 13, 2024 · Primary completion Dec 2025
Drug: DP303c; trastuzumab emtansine · For: HER2-positive Breast Cancer
Sites: Shanghai, China
- DP303c in Patients With HER2-positive Advanced Breast CancerPivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05901935 · 420 participants (planned) · Start Jul 2023 · Primary completion Jan 2026
Drug: DP303c; Trastuzumab and 2 more · For: HER2-positive Advanced Breast Cancer
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaPivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06577376 · 252 participants (planned) · Start Aug 26, 2024 · Primary completion Aug 26, 2026
Drug: DP303c; Simmitinib tablets and 2 more · For: Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04826107 · 196 participants (planned) · Start Aug 2021 · Primary completion Aug 2024
Drug: DP303c treatment; DP303c treatment(second-line of HER2-positive) and 3 more · For: Gastric Cancer
- DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast CancerStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05334810 · 191 participants (planned) · Start May 1, 2022 · Primary completion Dec 31, 2023
Drug: DP303c · For: HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04828616 · 104 participants (planned) · Start Jul 2021 · Primary completion Jul 2023
Drug: DP303c injection · For: Ovarian Cancer
Sites: Chongqing, China
- Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid TumorsStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04146610 · 30 participants (planned) · Start Nov 2019 · Primary completion Jun 2021
Drug: an antibody drug conjugate · For: Neoplasms
Sites: Shanghai, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05810103 · 12 participants (planned) · Start Apr 6, 2023 · Primary completion Dec 23, 2023
Drug: DP303c · For: HER2-positive Advanced Solid Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Liu F, Pan Y, Li J, et al. · Front Pharmacol 2026
- Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case.
Diao Y, Yin H, Sun X, et al. · Front Immunol 2025
- Antibody-drug conjugates in HER2-positive advanced or metastatic gastric cancer: a systematic review and meta-analysis.
Li J, Chen S, Chai Y, et al. · Front Oncol 2025
- First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.
Zhang J, Du Y, Meng Y, et al. · NPJ Precis Oncol 2024
- An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.
Hui X, Yuan C, Cao W, et al. · Onco Targets Ther 2022
Also in development for HER2-positive Breast Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials
Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors
- GQ1005Phase 31 trial
GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.